Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Philip Greenberg

Fred Hutchinson Cancer Research Center, Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Juno Therapeutics

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Dr. Greenberg has a significant financial interest in a company, Juno Therapeutics, that holds a license to intellectual property on which he is an inventor. That intellectual property will be used in carrying out certain aspects of this project.

Listed Research Project
Targeting Leukemia with Memory CD8+ T cells Transduced to Express High-Affinity W

In an attempt to eradicate recurrent leukemia after hematopoietic cell transplantation (HCT) which is associated with a very poor outcome, patients will receive infused white blood cells that are specific for common viruses (EBV and CMV), as they have the ability to survive longer, and that are genetically modified with a strong receptor for WT1, which is a protein contained by leukemia cells. This project then proposes to examine the safety of targeting a protein called CCNA1, which is contained in leukemia stem cells, and then perform the initial steps necessary to target this protein with a strong receptor that could be used for patients in the future. This research may help patients fight recurrent leukemia with a non-toxic approach that could be used to offset or delay HCT in future studies.

Filed on July 09, 2014.

Tell us what you know about Philip Greenberg's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Philip Greenberg Fred Hutchinson Cancer Research Center Conflict of Interest Juno Therapeutics >$600,000
Philip Greenberg Fred Hutchinson Cancer Research Center Conflict of Interest Juno Therapeutics >$600,000
Philip Greenberg Fred Hutchinson Cancer Research Center Conflict of Interest Juno Therapeutics Value cannot be readily determined
Philip Greenberg Fred Hutchinson Cancer Research Center Conflict of Interest Juno Therapeutics $60,000 - $79,999
Philip Greenberg Fred Hutchinson Cancer Research Center Conflict of Interest Juno Therapeutics $60,000 - $79,999
Philip Greenberg Fred Hutchinson Cancer Research Center Conflict of Interest Juno Therapeutics Value cannot be readily determined
Philip Greenberg Fred Hutchinson Cancer Research Center Conflict of Interest Juno Therapeutics $60,000 - $79,999
Philip Greenberg Fred Hutchinson Cancer Research Center Conflict of Interest Juno Therapeutics Value cannot be readily determined
Philip Greenberg Fred Hutchinson Cancer Research Center Conflict of Interest Juno Therapeutics Value cannot be readily determined
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page